Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew Weaver

Showing results (11-20 of 22) with videos related to

Pageof 3
Sort By:
Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual International Conference|January 24, 2009
Chemotherapy side-effect management using mobile phonesMark E Larsen, Joanna Rowntree, Annie M Young, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|August 6, 2005
An elevated matrix metalloproteinase (MMP) in an animal model of multiple sclerosis is protective by affecting Th1/Th2 polarizationAndrew Weaver, Angelika Goncalves da Silva, Robert K Nuttall, et al.
Cureus|April 4, 2025
Age-Related Differences in Pediatric Burn Characteristics: A Retrospective Analysis at Cabell Huntington HospitalArmein Rahimpour, Isabella G Stuart, Nathan Fox, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|April 29, 2014
A pilot study: dose adaptation of capecitabine using mobile phone toxicity monitoring - supporting patients in their homesAndrew Weaver, Sharon B Love, Mark Larsen, et al.
Radiographics : a Review Publication of the Radiological Society of North America, Inc|March 22, 2007
Anatomic and functional imaging of metastatic carcinoid tumorsAndrew F Scarsbrook, Arul Ganeshan, Jane Statham, et al.
The Lancet. Oncology|September 24, 2016
Adjuvant capecitabine plus bevacizumab versus capecitabine alone in patients with colorectal cancer (QUASAR 2): an open-label, randomised phase 3 trialRachel S Kerr, Sharon Love, Eva Segelov, et al.
Endocrine-Related Cancer|December 13, 2018
Peptide receptor radionuclide therapy in gastroenteropancreatic NEN G3: a multicenter cohort studyEsben Andreas Carlsen, Nicola Fazio, Dan Granberg, et al.
The Lancet. Oncology|August 8, 2017
First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 trialsHarpreet S Wasan, Peter Gibbs, Navesh K Sharma, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 20, 2021
Radioembolization With Chemotherapy for Colorectal Liver Metastases: A Randomized, Open-Label, International, Multicenter, Phase III TrialMary F Mulcahy, Armeen Mahvash, Marc Pracht, et al.
The Lancet. Oncology|April 4, 2018
3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trialTimothy J Iveson, Rachel S Kerr, Mark P Saunders, et al.
Pageof 3

Showing results (11-20 of 22) with videos related to

Sort By:
Pageof 3
Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual International Conference|January 24, 2009
Chemotherapy side-effect management using mobile phonesMark E Larsen, Joanna Rowntree, Annie M Young, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|August 6, 2005
An elevated matrix metalloproteinase (MMP) in an animal model of multiple sclerosis is protective by affecting Th1/Th2 polarizationAndrew Weaver, Angelika Goncalves da Silva, Robert K Nuttall, et al.
Cureus|April 4, 2025
Age-Related Differences in Pediatric Burn Characteristics: A Retrospective Analysis at Cabell Huntington HospitalArmein Rahimpour, Isabella G Stuart, Nathan Fox, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|April 29, 2014
A pilot study: dose adaptation of capecitabine using mobile phone toxicity monitoring - supporting patients in their homesAndrew Weaver, Sharon B Love, Mark Larsen, et al.
Radiographics : a Review Publication of the Radiological Society of North America, Inc|March 22, 2007
Anatomic and functional imaging of metastatic carcinoid tumorsAndrew F Scarsbrook, Arul Ganeshan, Jane Statham, et al.
The Lancet. Oncology|September 24, 2016
Adjuvant capecitabine plus bevacizumab versus capecitabine alone in patients with colorectal cancer (QUASAR 2): an open-label, randomised phase 3 trialRachel S Kerr, Sharon Love, Eva Segelov, et al.
Endocrine-Related Cancer|December 13, 2018
Peptide receptor radionuclide therapy in gastroenteropancreatic NEN G3: a multicenter cohort studyEsben Andreas Carlsen, Nicola Fazio, Dan Granberg, et al.
The Lancet. Oncology|August 8, 2017
First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 trialsHarpreet S Wasan, Peter Gibbs, Navesh K Sharma, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 20, 2021
Radioembolization With Chemotherapy for Colorectal Liver Metastases: A Randomized, Open-Label, International, Multicenter, Phase III TrialMary F Mulcahy, Armeen Mahvash, Marc Pracht, et al.
The Lancet. Oncology|April 4, 2018
3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trialTimothy J Iveson, Rachel S Kerr, Mark P Saunders, et al.
Pageof 3